DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20191765

Usefulness of fibro scan in assessing liver fibrosis in adult patients with psoriasis

Parimalam Kumar, Suchithra Ganapathi, Athilakshmi Sivasubramanian

Abstract


Background: Patients with psoriasis are at higher risk of developing “systemic” co-morbidities. Non alcoholic fatty liver disease (NAFLD) is found to be more prevalent among psoriasis patients, where it is closely associated with obesity, metabolic syndrome, and psoriatic arthropathy. Elderly participants with psoriasis are 70% more likely to have NAFLD than those without psoriasis independent of common NAFLD risk factors.Methotrexate is a commonly used drug in the management of psoriasis owing to its cost effectiveness and easy administration. In the presence of NAFLD the choice of potentially hepatotoxic drug therapy, such as methotrexate, should be considered with caution. By assessing the liver stiffness measurement (LSM), such drugs can be prescribed with caution in individual with significant liver fibrosis. We have conducted a study to assess the LSM in patients with psoriasis. Aim was to detect the proportion of liver fibrosis (LSM) in adult patients with psoriasis, which will help in choosing the correct treatment.

Methods: Hospital based cross sectional study was conducted in 102 adults with psoriasis who were not treated with methotrexate. Transient elastography (TE) was performed in all and LSM was noted.

Results: There was no statistically significant gender influence on LSM in patients with psoriasis. There was significant increase in liver fibrosis in psoriatic patients as age advances.

Conclusions: Elderly patients with psoriasis are more likely to have liver fibrosis. Hepatotoxic drugs like methotrexate should be prescribed with caution in such patients, preferably after performing LSM.


Keywords


Fibro scan, Liver fibrosis, Methotrexate, Psoriasis

Full Text:

PDF

References


Van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol. 2014;70:517–24.

Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778–86.

Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes Indian J Endocrinol Metab. 2015;19(5):597–601.

Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of Severe Liver Disease in Nonalcoholic Fatty Liver Disease with Normal Aminotransferase levels: A Role for Insulin Resistance and Diabetes. Hepatology. 2008;48:792-8.

Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol. 2016;22(32):7236-51.

Lynch M, Higgins E, McCormick PA, Kirby B, Nolan N, Rogers S, et al. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis. JAMA Dermatology. 2014;150(8):856–62.

Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. British J Dermatol. 2014;171(1):17–29.

Pongpit J, Porntharukchareon S, Kaewduang P, Promson K, Stitchantrakul W, Petraksa S, et al. Liver Stiffness Measurement in Psoriasis: Do Metabolic or Disease Factors Play the Important Role? Biomed Res Int. 2016;2016:7963972.

Rosenberg P, Urwitz H, Johannesson A, Ros AM, Lindholm J, Kinnman N, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol. 2007;46(6):1111–8.

Narayanasamy K, Sanmarkan AD, Rajendran K, Annasamy C, Ramalingam S. Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol. 2016;11(4):263-9.

Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758–64.

Roberts KK, Cochet AE, Lamb PB, Brown PJ, Battafarano DF, Brunt EM, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther. 2015;41:293–300.

Alsebaey A, Allam N, Alswat K, Waked I. Normal liver stiffness: A study in living donors with normal liver histology. World J Hepatol. 2015;7(8):1149–53.

Fung J, Lee C, Chan M, Seto W, Wong DK, Lai C, et al. Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. PLoS One. 2013;8(12):e85067.

Huang Z, Zheng J, Zeng J, Wang X, Wu T, Zheng R. Normal liver stiffness in healthy adults assessed by real-time shear wave elastography and factors that influence this method. Ultrasound Med Biol. 2014;40(11):2549-55.

Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat. 2007;14:360–9.

Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.

Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology. 2007;47:592–5.

Millonig G, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Buchler MW, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718–23.

Prussick R, Prussick L, Nussbauma D. Nonalcoholic Fatty Liver Disease and Psoriasis What a Dermatologist Needs to Know. J Clin Aesthet Dermatol. 2015;8(3):43–5.